The American Association for Cancer Research (AACR) announces its collaboration with the clinical trial navigation system EmergingMed, to connect patients with clinical trials in connection to the Stand Up To Cancer (SU2C) broadcast which took place on Sept. 10, at 8 p.m. EDT & PDT / 7 p.m. CDT. The AACR-SU2C Clinical Trials Finder provides a resource for cancer patients and their loved ones to identify clinical trials that may be appropriate for their particular diagnosis, stage and treatment history.
"The AACR is thrilled to partner with EmergingMed, in conjunction with the landmark SU2C broadcast on Sept. 10, in order to help patients locate clinical trials for which they qualify," said Margaret Foti, Ph.D., M.D. (h.c.), CEO of the American Association for Cancer Research. "SU2C's mission is to provide effective treatments to patients quickly, and this partnership with EmergingMed helps realize that goal. Moreover, the AACR aims to educate the public about what clinical trials can offer, in order to help patients make educated decisions about their treatment options."
The AACR is the sole scientific partner to SU2C. It is responsible for grants administration and management, and provides ongoing scientific oversight in conjunction with the SU2C Scientific Advisory Committee, led by Nobel Laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
The SU2C show, featuring cancer researchers as well as luminaries from film, TV, music, news and sports, was simulcast live on ABC, CBS, FOX, NBC, on more than a dozen other networks, and aired in more than 195 countries. Funds raised will fuel groundbreaking translational research around the world to accelerate the delivery of new therapies to patients.
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts